Immediate Impact
69 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
2024 Standout
Works of Elke Pfaff being referenced
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
2018
Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²).
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Elke Pfaff | 76 | 44 | 24 | 52 | 10 | 121 | |
| Saewon Chun | 107 | 33 | 17 | 42 | 8 | 141 | |
| Alicia Steffens | 78 | 34 | 17 | 32 | 9 | 126 | |
| Jochen Tüttenberg | 94 | 38 | 31 | 17 | 9 | 184 | |
| Jinping Liu | 61 | 50 | 31 | 33 | 8 | 138 | |
| Lihong Long | 117 | 101 | 37 | 64 | 12 | 185 | |
| Yunbo Zhan | 48 | 51 | 21 | 31 | 9 | 129 | |
| Daniel I. Jacobs | 78 | 117 | 14 | 65 | 8 | 222 | |
| Javal Sheth | 50 | 67 | 11 | 20 | 10 | 156 | |
| Evangeline R. Jackson | 69 | 54 | 23 | 20 | 7 | 115 | |
| Christine McCluskey | 88 | 88 | 57 | 23 | 11 | 183 |
All Works
Login with ORCID to disown or claim papers
Loading papers...